A national pharmacogenetics testing service

Impact Summary for the General Public

Our research concerning the economics of pharmacogenetic testing: (i) led to the development of a CE-marked commercial product with MC Diagnostics, which is used in the Netherlands; (ii) informed the delivery of pharmacogenetics in response to the Welsh Government’s Genomics for Precision Medicine Strategy; and (iii) underpinned the decision of NHS England / Genomics England to pilot a national pharmacogenetics service. This service is relevant to 42 prescribed medications, which are likely to be prescribed to 85% of the population over their lifetimes. If just 1% of eligible patients were tested, representing 42,000 tests annually, 2,800 adverse drug reactions could be avoided.

Category of impact

  • Health/Quality of life

Research outputs (6)

View all